Clinical trial NCT00744250: Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
Official title: Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Exocrine Pancreatic Insufficiency
Chronic Pancreatitis
Cystic Fibrosis
Keywords: Exocrine Pancreatic Insufficiency
Chronic Pancreatitis
Cystic fibrosis
Pancrelipase
Pancrecarb
Intraduodenal aspiration
Bioavailability
Lead sponsor: Digestive Care, Inc.
Sponsor class: INDUSTRY
Collaborators: name: University of North Carolina, Chapel Hill
First posted: 2008-08-29
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this research study is to learn about the activity of oral Pancrecarb® (a pancreatic enzyme preparation which contains proteins that help to digest food), administered by mouth as a capsule filled with specially coated granules in patients taking exogenous pancreatic enzyme therapy. Specific enzymes activities will be determined from samples of stomach and intestinal fluids after a standard liquid meal.

Detailed description: Purpose:

The purpose of this study is to assess the bioavailability of oral Pancrecarb® (exogenous pancreatic enzyme administered orally as a capsule filled with enteric coated granules) compared to placebo control in patients with pancreatic insufficiency. Lipase, amylase and protease activities will be determined from stomach and duodenal aspirates after standard meal stimulation.

Participants:

Patients with pancreatic insufficiency will be recruited as the study population.

Procedures (methods):

Eligible subjects will undergo an initial screening phase and will provide a stool sample to confirm pancreatic exocrine insufficiency based on a spot fecal elastase-1 of \< 75 mcg/g stool. Within one month after the screening phase, subjects meeting inclusion criteria will be scheduled to arrive in the GCRC by 7pm. If the subject is a female of child bearing age, a serum pregnancy test will be checked. At 7am the subject will be escorted to fluoroscopy for placement of an oro-enteric tube. Once the tip of the tube has been positioned in the duodenum, the subject will be escorted back to the GCRC. Prior to administration of the capsules and liquid diet, baseline gastric and duodenal secretions will be aspirated via the oro-enteric tube by the investigators. Subjects will then receive 5 capsules of active drug with a standard liquid Lundh diet of 360 mL over a 10 minute period, administered to simulate a fed state. Then duodenal and gastric secretions will be aspirated from the tube over a 3-hour period. At the end of the 3 hours, the subject will be allowed to rest for 60 minutes. The second phase will consist of 5 capsules of placebo again with a standard liquid Lundh diet , and another 3-hour aspiration phase. After the second 3-hour aspiration period, the balloon will be deflated and the tube will be removed. Subjects will be observed for 30 minutes and then discharged.

Eligibility criteria: Inclusion Criteria:

* Documented pancreatic enzyme insufficiency as determined by spot fecal elastase-1 (\<75 mcg/g) at the time of screening
* Required daily exogenous enzyme supplementation with commercially available pancreatic enzymes
* ≥ 18 years of age
* Male and female subjects
* Able to swallow capsules
* Clinically stable with no evidence of an acute medical conditions

Exclusion Criteria:

* History of fibrosing colonopathy in cystic fibrosis subjects
* Current diagnosis or a history of distal intestinal obstruction syndrome (DIOS) in the past 4 months
* Known contraindications, sensitivity or hypersensitivity to porcine pancreatic enzymes, benzocaine or similar products
* Women with a positive serum beta-hCG at the time of screening or the day of the study (due to radiation exposure)
* Liver disease
* ALT or AST ≥ 3 time the upper limit of normal
* Bilirubin ≥ 3 times the upper limit of normal
* Acute pancreatitis or acute exacerbation of chronic pancreatitis within 90 days
* Use of medications which affect with intestinal transit (example, narcotics, erythromycin, metoclopramide etc.)
* Subjects receiving treatment with antacids, H2 receptor blockers, or proton pump inhibitors and unable to discontinue these within 72 hr prior to the study day
* Diabetes mellitus
* A medical condition which the investigator deems significant enough to interfere with the ability of the subject to participate in the intubation study or interfere with the assessment of enzyme bioavailability
* Small bowel disease (i.e. celiac disease)
* Lactose intolerance
* History of gastric resection

Primary outcomes:
measure: Peak levels of three enzymes - lipase, amylase, and protease - each measured in U/ml will be outcomes
timeFrame: Samples will be collected over two consecutive 3 hour study periods and sent for analysis
Secondary outcomes:
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: UNC Healthcare
state: North Carolina
Study officials:
affiliation: University of North Carolina, Chapel Hill
name: Lisa Gangarosa, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: UNC School of Pharmacy
name: Kim Brouwer, PharmD, PhD
role: PRINCIPAL_INVESTIGATOR
References: